Twitter icon Email alerts icon Latest News RSS icon Magazine icon Stay connected:

View the article online at

Overnight Markets: US stocks gain on Yellen's statement

by Himanshu Singh on Apr 01, 2014 at 04:24

Overnight Markets: US stocks gain on Yellen's statement

Wall Street rose on Monday, with the Standard & Poor’s 500 Index posting a fifth quarterly gain, after Federal Reserve Chair Janet Yellen relieved concerns about a rate increase coming earlier than expected and tensions appeared to ease in Ukraine.

The Dow Jones industrial average surged 135 points, or 0.82%, to end at 16,458. The Standard & Poor's 500 Index rose 15 points, or 0.79%, to close at 1,872. The Nasdaq Composite Index climbed 43 points, or 1.04%, to finish at 4,199.

This was the fifth consecutive quarterly rise for both the S&P 500 and the Nasdaq, though it was the smallest three-month advance for both since the fourth quarter of 2012.

Yellen said yesterday ‘‘considerable slack’’ in the labour market is evidence that the central bank’s unprecedented accommodation will still be needed for “some time” to put Americans back to work.

Equities also received a boost from end-of-quarter "window dressing," when money managers adjust positions to improve the look of their portfolios.

Economic data showed, the Institute for Supply Management-Chicago Inc.’s business barometer fell to 55.9 from 59.8 in February. Economists surveyed by Bloomberg expected a drop to 59.5.

Meanwhile, Russia and the US agree on the need for a diplomatic solution to tensions over Ukraine, Russian Foreign Minister Sergei Lavrov said.

Materials and utility sector gained the most. Technology and financial shares also outperformed for the day. However, biotech stocks stayed in focus following recent volatility when investors sharply took profits in the high-flying sector.

Micron Tech (MU.O) climbed 8%, ranking as the S&P 500's top percentage gainer. Oracle Corp (ORCL.N) rose 3.4%. Vertex Pharmaceuticals (VRTX.O) climbed 4.3% and Biogen Idec (BIIB.O) added 4%.

US-listed shares of Prana Biotechnology Ltd (PRAN.O) plunged 71.6% after the company said its experimental drug to treat Alzheimer's disease failed to meet the main goal of a mid-stage study in patients with a mild form of the condition.

Sign in / register to view full article on one page

leave a comment

Please sign in here or register here to comment. It is free to register and only takes a minute or two.

News sponsored by:

Sponsored Video: Bringing it all back home

As the UK coalition government strives to rebalance the national economy, so called 'reshoring' looks set to play an increasingly important role in economic recovery.

Today's top headlines

Sponsored Video: Barings on investing in Frontier Markets

From Nigeria to Pakistan and from Kenya to Kuwait, frontier markets are catching investors' attention as never before.

More about this:


On the road

Click here to find out more from the Audience Development team.

Sorry, this link is not
quite ready yet